Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 10
1988 9
1989 14
1990 6
1991 7
1992 21
1993 13
1994 15
1995 10
1996 19
1997 14
1998 17
1999 9
2000 14
2001 12
2002 10
2003 15
2004 10
2005 10
2006 14
2007 16
2008 11
2009 15
2010 20
2011 25
2012 19
2013 27
2014 33
2015 37
2016 41
2017 40
2018 48
2019 58
2020 66
2021 73
2022 65
2023 73
2024 74
2025 101
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

961 results

Results by year

Filters applied: . Clear all
Page 1
NCCN Guidelines Insights: Rectal Cancer, Version 3.2024.
Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Jones F, Gurski L. Benson AB, et al. J Natl Compr Canc Netw. 2024 Aug;22(6):366-375. doi: 10.6004/jnccn.2024.0041. J Natl Compr Canc Netw. 2024. PMID: 39151454
Particularly for patients with distal rectal cancer, finding a balance between curative-intent therapy while having minimal impact on quality of life can be challenging. Furthermore, the risk of pelvic recurrence is higher in patients with rectal cancer …
Particularly for patients with distal rectal cancer, finding a balance between curative-intent therapy while having minimal im …
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Jeck W, Johung KL, Kirilcuk N, Krishnamurthi S, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Gregory K, Gurski L. Benson AB, et al. J Natl Compr Canc Netw. 2022 Oct;20(10):1139-1167. doi: 10.6004/jnccn.2022.0051. J Natl Compr Canc Netw. 2022. PMID: 36240850
This selection from the NCCN Guidelines for Rectal Cancer focuses on management of malignant polyps and resectable nonmetastatic rectal cancer because important updates have been made to these guidelines. These recent updates include redrawing the algo …
This selection from the NCCN Guidelines for Rectal Cancer focuses on management of malignant polyps and resectable nonmetastat …
Preoperative Treatment of Locally Advanced Rectal Cancer.
Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, Goldberg J, Al Baghdadi T, Goodman KA, McWilliams RR, Farma JM, George TJ, Kennecke HF, Shergill A, Montemurro M, Nelson GD, Colgrove B, Gordon V, Venook AP, O'Reilly EM, Meyerhardt JA, Dueck AC, Basch E, Chang GJ, Mamon HJ. Schrag D, et al. N Engl J Med. 2023 Jul 27;389(4):322-334. doi: 10.1056/NEJMoa2303269. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272534 Free PMC article. Clinical Trial.
BACKGROUND: Pelvic radiation plus sensitizing chemotherapy with a fluoropyrimidine (chemoradiotherapy) before surgery is standard care for locally advanced rectal cancer in North America. Whether neoadjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplati …
BACKGROUND: Pelvic radiation plus sensitizing chemotherapy with a fluoropyrimidine (chemoradiotherapy) before surgery is standard care for l …
Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer.
Chatila WK, Kim JK, Walch H, Marco MR, Chen CT, Wu F, Omer DM, Khalil DN, Ganesh K, Qu X, Luthra A, Choi SH, Ho YJ, Kundra R, Groves KI, Chow OS, Cercek A, Weiser MR, Widmar M, Wei IH, Pappou EP, Nash GM, Paty PB, Shi Q, Vakiani E, Duygu Selcuklu S, Donoghue MTA, Solit DB, Berger MF, Shia J, Pelossof R, Romesser PB, Yaeger R, Smith JJ, Schultz N, Sanchez-Vega F, Garcia-Aguilar J. Chatila WK, et al. Nat Med. 2022 Aug;28(8):1646-1655. doi: 10.1038/s41591-022-01930-z. Epub 2022 Aug 15. Nat Med. 2022. PMID: 35970919 Free PMC article.
The incidence of rectal cancer is increasing in patients younger than 50 years. Locally advanced rectal cancer is still treated with neoadjuvant radiation, chemotherapy and surgery, but recent evidence suggests that patients with a complete response ca …
The incidence of rectal cancer is increasing in patients younger than 50 years. Locally advanced rectal cancer i …
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C; FRESCO-2 Study Investigators. Dasari A, et al. Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15. Lancet. 2023. PMID: 37331369 Clinical Trial.
BACKGROUND: There is a paucity of effective systemic therapy options for patients with advanced, chemotherapy-refractory colorectal cancer. We aimed to evaluate the efficacy and safety of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial gr …
BACKGROUND: There is a paucity of effective systemic therapy options for patients with advanced, chemotherapy-refractory colorectal cance …
MRI for Rectal Cancer: Staging, mrCRM, EMVI, Lymph Node Staging and Post-Treatment Response.
Bates DDB, Homsi ME, Chang KJ, Lalwani N, Horvat N, Sheedy SP. Bates DDB, et al. Clin Colorectal Cancer. 2022 Mar;21(1):10-18. doi: 10.1016/j.clcc.2021.10.007. Epub 2021 Nov 14. Clin Colorectal Cancer. 2022. PMID: 34895835 Free PMC article. Review.
Rectal cancer is a relatively common malignancy in the United States. Magnetic resonance imaging (MRI) of rectal cancer has evolved tremendously in recent years, and has become a key component of baseline staging and treatment planning. ...This review …
Rectal cancer is a relatively common malignancy in the United States. Magnetic resonance imaging (MRI) of rectal can …
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048).
Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, Gollub M, Rogak L, Ginos B, Mazza GL, Colgrove B, Chang G, Minasian L, Denicoff A, Thanarajasingam G, Musher B, George T, Venook A, Farma J, O'Reilly E, Meyerhardt JA, Shi Q, Schrag D. Basch E, et al. J Clin Oncol. 2023 Jul 20;41(21):3724-3734. doi: 10.1200/JCO.23.00903. Epub 2023 Jun 4. J Clin Oncol. 2023. PMID: 37270691 Free PMC article. Clinical Trial.
PURPOSE: The standard of care for locally advanced rectal cancer in North America is neoadjuvant pelvic chemoradiation with fluorouracil (5FUCRT). ...CONCLUSION: For patients with locally advanced rectal cancer choosing between neoadjuvant FOLFOX and 5 …
PURPOSE: The standard of care for locally advanced rectal cancer in North America is neoadjuvant pelvic chemoradiation with fl …
Future direction of total neoadjuvant therapy for locally advanced rectal cancer.
Kagawa Y, Smith JJ, Fokas E, Watanabe J, Cercek A, Greten FR, Bando H, Shi Q, Garcia-Aguilar J, Romesser PB, Horvat N, Sanoff H, Hall W, Kato T, Rödel C, Dasari A, Yoshino T. Kagawa Y, et al. Nat Rev Gastroenterol Hepatol. 2024 Jun;21(6):444-455. doi: 10.1038/s41575-024-00900-9. Epub 2024 Mar 14. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38485756 Free PMC article. Review.
Despite therapeutic advancements, disease-free survival and overall survival of patients with locally advanced rectal cancer have not improved in most trials as a result of distant metastases. For treatment decision-making, both long-term oncologic outcomes and impa …
Despite therapeutic advancements, disease-free survival and overall survival of patients with locally advanced rectal cancer h …
MRI for Rectal Cancer: Updates and Controversies-AJR Expert Panel Narrative Review.
Khasawneh H, Khatri G, Sheedy SP, Nougaret S, Lambregts DMJ, Santiago I, Kaur H, Smith JJ, Horvat N. Khasawneh H, et al. AJR Am J Roentgenol. 2025 Jun;224(6):e2431523. doi: 10.2214/AJR.24.31523. Epub 2024 Sep 25. AJR Am J Roentgenol. 2025. PMID: 39320354 Free PMC article. Review.
Rectal MRI is a critical tool in the care of patients with rectal cancer, having established roles for primary staging, restaging, and surveillance. ...In this AJR Expert Panel Narrative Review, we address recent advances and key areas of contention related t …
Rectal MRI is a critical tool in the care of patients with rectal cancer, having established roles for primary staging, …
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez E, Bajor DL, Cremolini C, Sanchez F, Stecher M, Feng W, Bekaii-Saab TS; MOUNTAINEER investigators. Strickler JH, et al. Lancet Oncol. 2023 May;24(5):496-508. doi: 10.1016/S1470-2045(23)00150-X. Lancet Oncol. 2023. PMID: 37142372 Clinical Trial.
BACKGROUND: HER2 is an actionable target in metastatic colorectal cancer. We assessed the activity of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer. ...This treatment is …
BACKGROUND: HER2 is an actionable target in metastatic colorectal cancer. We assessed the activity of tucatinib plus trastuzumab in p …
961 results